# AstraZeneca acquires Omniose and its vaccine manufacturing platform

_Published Tuesday, November 10, 2026 at 2:09 PM EST · Capital · Latest · Tier 2 — Notable_

![AstraZeneca acquires Omniose and its vaccine manufacturing platform — Primary](https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png)

AstraZeneca has acquired Omniose, a preclinical biotechnology company developing vaccines against serious bacterial infections, following three years of exclusive research collaboration. Omniose becomes a wholly owned subsidiary, bringing its technology and expertise into AstraZeneca's Infectious Disease Unit, RTTNews reported.

The platform uses an enzyme to produce and link bacterial polysaccharides and carrier proteins within a single cell. Traditional manufacturing attaches those components through chemical processes. AstraZeneca plans to integrate the platform into its vaccine capabilities and preclinical programs. Financial terms were not disclosed.

## Sources

- [RTTNews](https://www.rttnews.com/3712661/astrazeneca-gains-single-cell-bioconjugation-technology-through-omniose-deal.aspx)

---
Canonical: https://techandbusiness.org/newswire/h80iQQLWWteaDM4gDiJm8U
Published: 2026-11-10T19:09:53.056Z
Story chronology: 2026-11-10T15:52:43.000Z
Retrieved: 2026-11-10T20:48:54.754Z
Publisher: Tech & Business (techandbusiness.org)